247 related articles for article (PubMed ID: 9049879)
1. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
2. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
3. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma.
Williams JA; Yuan X; Dillehay LE; Shastri VR; Brem H; Williams JR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):631-9. PubMed ID: 9806525
[TBL] [Abstract][Full Text] [Related]
4. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas.
Yuan X; Dillehay LE; Williams JR; Shastri VR; Williams JA
Int J Cancer; 2001 Apr; 96(2):118-25. PubMed ID: 11291095
[TBL] [Abstract][Full Text] [Related]
5. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
6. Synthetic, implantable, biodegradable polymers for controlled release of radiosensitizers.
Yuan X; Fahlman C; Tabassi K; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):177-86. PubMed ID: 10850302
[TBL] [Abstract][Full Text] [Related]
7. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
[TBL] [Abstract][Full Text] [Related]
9. Protracted exposure radiosensitization of experimental human malignant glioma.
Williams JA; Williams JR; Yuan X; Dillehay LE
Radiat Oncol Investig; 1998; 6(6):255-63. PubMed ID: 9885941
[TBL] [Abstract][Full Text] [Related]
10. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
13. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
[TBL] [Abstract][Full Text] [Related]
14. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas.
Pradilla G; Legnani FG; Petrangolini G; Francescato P; Chillemi F; Tyler BM; Gaini SM; Brem H; Olivi A; DiMeco F
Neurosurgery; 2005 Nov; 57(5):1032-40; discussion 1032-40. PubMed ID: 16284573
[TBL] [Abstract][Full Text] [Related]
15. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.
Walter KA; Cahan MA; Gur A; Tyler B; Hilton J; Colvin OM; Burger PC; Domb A; Brem H
Cancer Res; 1994 Apr; 54(8):2207-12. PubMed ID: 7909720
[TBL] [Abstract][Full Text] [Related]
16. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
[TBL] [Abstract][Full Text] [Related]
17. Brain biocompatibility of a biodegradable, controlled-release polymer in rats.
Tamargo RJ; Epstein JI; Reinhard CS; Chasin M; Brem H
J Biomed Mater Res; 1989 Feb; 23(2):253-66. PubMed ID: 2708412
[TBL] [Abstract][Full Text] [Related]
18. Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain.
Reza MS; Whateley TL
J Microencapsul; 1998; 15(6):789-801. PubMed ID: 9818956
[TBL] [Abstract][Full Text] [Related]
19. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma.
Deutsch M; Rewers AB; Redgate S; Fisher ER; Boggs SS
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):85-7. PubMed ID: 2380099
[TBL] [Abstract][Full Text] [Related]
20. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
